Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Biocatalytic Reduction. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
This patent details a novel biocatalytic route for sitagliptin intermediates offering high purity and yield. It enables significant cost reduction and supply chain reliability for pharmaceutical manufacturing partners.
Patent CN103555608B reveals high-efficiency biocatalytic route for chiral intermediate. Enables cost reduction and supply chain reliability for pharma.
Patent CN106754775B details ScCR1 mutants for Atorvastatin intermediate. Offers high stability and activity for cost-effective manufacturing.
Novel biocatalytic route for chloramphenicol synthesis offering high yield and reduced waste. Ideal for reliable antibiotic supplier partnerships.
Patent CN105039432A details Penicillium biocatalysis for high-purity chiral intermediates. Achieve substantial cost reduction and supply chain reliability.
Patent CN10508767673A reveals high-yield biocatalytic route. Offers supply chain stability and cost reduction in chiral intermediate manufacturing for global partners.
Patent CN101665811A reveals high-ee biocatalytic route for ACEI intermediates, offering superior purity and scalable production capabilities.
Patent CN104263769A details yeast-based reduction for high-purity chiral intermediates. Offers scalable, cost-effective manufacturing solutions for global supply chains.
Patent CN104232696B enables high ee biocatalysis for pharmaceutical intermediates with significant cost and supply chain advantages for global buyers.
Novel enzymatic route for (R)-HPBE offers high purity and yield. Reduces cost and supply chain risks for lisinopril intermediate manufacturing globally.
Patent CN105732373A details high-purity (R)-HPBE production via enzymatic reduction. This method offers significant supply chain and cost advantages for pharmaceutical intermediates manufacturing.
Patent CN108220358A reveals high-yield biocatalytic route for chiral intermediates. Achieve superior purity and supply chain reliability for pharmaceutical manufacturing.
Patent CN110129382B details a green enzymatic route for high-purity chiral alcohols, offering significant supply chain stability and cost efficiency for pharmaceutical intermediates.
Patent CN1497048A details a biocatalytic route for chiral intermediates. Offers high ee and scalable production for pharma applications.
Patent CN101319236A details a green biocatalytic method for chiral alcohols using ionic liquids. Achieve high purity and cost reduction in pharma intermediate manufacturing with scalable processes.
Novel biocatalytic route for chiral alcohol intermediates ensures >99% ee and scalable production for beta-3 agonists.